'Methodical' Blend Therapeutics shuns large A round, to build drug combinations company

 
• By Nancy Faigen
  
Generate a summary of this article
Listen to this article
Beta

Raising money for a new drug development company, Blend Therapeutics has deliberately followed a softly, softly approach to funding, according to its stellar scientific founders. The Watertown, Massachusetts-based company backed by the venture capital firms Flagship Ventures, New Enterprise Associates and NanoDimension, gained $2.8 million in a Series A funding round on 10 January 2012. It will work without a CEO until certain technical hurdles have been overcome.

Raising money for a new drug development company, Blend Therapeutics has deliberately followed a softly, softly approach to funding, according to its stellar scientific founders. The Watertown, Massachusetts-based company backed by the venture capital firms Flagship Ventures, New Enterprise Associates and NanoDimension, gained $2.8 million in a Series A funding round on 10 January 2012. It will work without a CEO until certain technical hurdles have been overcome.

Boston-based founders, Drs Robert Langer (from MIT) and Omid Farokhzad (from Harvard Medical School), along with colleague Dr Stephen Lippard...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.